Characterization of HIV-1 drug resistance among patients with failure of second-line combined antiretroviral therapy in central Ethiopia.
Tafese Beyene TufaAndre FuchsHans Martin OrthNadine LübkeElena KnopsEva HegerGodana JarsoZewdu HurissaYannik EggersDieter HäussingerTom LueddeBjörn-Erik Ole JensenRolf KaiserTorsten FeldtPublished in: HIV medicine (2021)
We found a high prevalence of resistance mutations, also against PIs (40%), as the national standard second-line cART components. Resistance testing before switching to second- or third-line cART is warranted.